New York, NY, March 04, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced ...
IGF-1R inhibition effect on a yes/SFK bypass resistance pathway: Rational basis for cotargeting IGF-1R and yes/SFK kinase in rhabdomyosarcoma. Preclinical evidence of craniofacial adverse effect of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results